We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance

By LabMedica International staff writers
Posted on 28 May 2026

Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. More...

With an estimated 1.5 billion people affected worldwide and MASLD now impacting 38% of the global population, clinicians need scalable, noninvasive tools that use routine laboratory data to identify high-risk patients sooner and standardize referrals. A new system has launched to address this need by combining certified algorithms with biomarker-based diagnostics across the liver care pathway.

Roche (Basel, Switzerland) has launched the Liver Disease Panel, a comprehensive library of certified healthcare algorithms designed to support chronic liver disease management from early risk identification to cancer surveillance. Available on the navify Algorithm Suite, the panel integrates with existing hospital systems to provide a single point of access for ordering and reviewing algorithm outputs. The solution is being rolled out in markets across Europe.

The panel combines biomarker-based diagnostics with advanced digital algorithms to enable noninvasive assessment using routinely available clinical data. A key component is LiverPRO, a CE‑marked algorithm developed with the health tech company Evido. LiverPRO adapts to existing patient data, requiring age and a minimum of three out of nine common blood-based biomarkers to assess the risk of liver fibrosis, enabling timely identification and standardized referrals.

Additional tools in the library include ADAPT used with Elecsys PRO‑C3 to assess fibrosis severity and GAAD used with Elecsys AFP and Elecsys PIVKA II to aid in the diagnosis of hepatocellular carcinoma. The platform also consolidates widely used clinical scores, including FIB‑4, MELD, ALBI, Child‑Pugh, and the Lille Model, into a single secure environment. Each solution is certified and automated within clinical workflows, with patient data handled to the standards required for a medical device.

Roche states that this approach reduces reliance on invasive testing and supports a proactive, preventive model of care. LiverPRO has been endorsed in the EASL Patient Trajectory Guidance as an alternative and scalable first‑line test for liver fibrosis. The navify platform supporting the panel is ISO/IEC 27001 certified, encrypts data at rest and in transit, and is operated in compliance with HIPAA and GDPR.

“Chronic liver disease impacts millions of lives around the world, and patients need effective care at every stage of their journey,” said Matt Sause, CEO Roche Diagnostics. “With the Liver Disease Panel, we are enabling clinicians to identify risk earlier, intervene sooner, and manage this disease more effectively, helping to improve liver care and support better patient health.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.